Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein

Peking University Third Hospital1,000 enrolled

Overview

The purpose of this study is to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.

This project is a single-center retrospective cohort study to obtain the biochemical index levels of urinary albumin creatinine ratio, urinary protein creatinine ratio, blood renal function, blood lipids, and blood glucose at the immediate, 3rd, 6th, and 12th month of cohort inclusion in each group of patients.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Type 2 Diabetes Antidiabetic Drugs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age greater than or equal to 18 years * Clinical diagnosis of type 2 diabetes mellitus * Immediate urine albumin creatinine ratio greater than 30mg/g * Signed informed consent and available for follow-up Exclusion Criteria: * severe renal insufficiency, i.e. eGFR ≤ 30ml/min/1.75m2 * clinical diagnosis of various acute and chronic urinary tract infections * combined with various serious infectious diseases * combined with acute complications of diabetes mellitus * end-stage malignancy * pregnancy and lactation

Locations (2)

Peking University Third Hospital, Beijing, Beijing 100191

Beijing, Beijing Municipality, China

RECRUITING

Peking University Third Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

urinary protein changes

to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.

Time frame: 2023.03-2024.03

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.